## U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

**SHEET** 

Attorney's Docket No. 033364-002

To the Honorable Commissioner of Patents and Trademarks.	Please record the attached original documents or copy thereof.				
1. Name of conveying party(ies): 6 - 14-02	2. Name and address of receiving party(ies):				
The Liposome Company, Inc.	Name: Elan Pharmaceuticals, Inc.				
Additional name(s) of companing neutrino) attached?	Address: 800 Gateway Boulevard				
Additional name(s) of conveying party(ies) attached? [ ] Yes [x] No	South San Francisco, CA 94080				
3. Nature of conveyance:					
[ ] Assignment [x] Merger [ ] Security Agreement [ ] Change of Name					
Other:					
Execution Date: December 28, 2001	Additional name(s) & address(es) attached? [ ] Yes [ x] No				
4. Application number(s) or patent number(s):					
If this document is being filed together with a new application, the execution date of the application is:					
A. Patent Application No.(s)	B. Patent No.(s)				
09/429,694	4,564,599				
Additional numbers attached? [x] Yes [] No (See Attatched Schedule A; See Attatched Schedule B for application and patent details)					
<ol><li>Name and address of party to whom correspondence concerning document should be mailed:</li></ol>	6. Total number of applications and patents involved: 151				
Name: Teresa Stanek Rea	7. Total fee (37 CFR § 3.41): \$\(\frac{6040.00}{\}\)				
Address: Burns, Doane, Swecker & Mathis, L.L.P.	[X] Enclosed				
P.O. Box 1404	[X] Authorized to be charged to deposit account, if necessary				
Alexandria, Virginia 22313-1404	8. Deposit account number:				
	5. Zopost uccount number.				
DO NOT USE	•				
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true a	THIS SPACE				
9. Statement and signature.	THIS SPACE  THIS SPACE  The copy of the original document.  June 14, 2002				
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true a  Teresa Stanek Rea, Reg. No. 30,427	THIS SPACE  THIS SPACE  THIS space of the original document.				

Commissioner of Patents and Trademarks Box Assignments Washington, D.C. 20231 06/19/2002 DBYRME 00000097 09429694 6040.00 DØ

01 FC:581

(10/01)

## Schedule A Continuation of Recordation Cover Sheet form PTO-1595

		101111 1 10-1373		
A. Patent Application	B. Patent Numbers			
Numbers				
09/429,694	4,668,638	5,100,662	5,756,774	5,703,117
09/540,050	4,897,834	5,376,381	4,666,831	6,051,600
09/976,936	5,059,591	5,200,393	4,698,299	6,107,332
09/645,973	5,366,958	5,762,958	6,261,792	6,392,063
08/442,077	5,000,958	5,965,159	4,522,803	5,082,664
09/398,934	5,030,453	5,942,246	4,588,578	5,262,168
09/644,470	5,169,637	6,007,839	5,429,823	5,925,375
09/715,798	4,714,571	6,180,137	5,783,210	5,188,951
07/323,182	4,814,111	5,897,873	5,556,580	5,762,957
08/439,227	5,084,215	5,820,848	5,583,052	
08/430,661	4,708,861	6,086,851	5,622,713	
10/132,151	4,721,612	6,090,406	5,008,050	
08/472,843	4,891,208	5,916,588	5,616,341	
09/940,672	5,231,112	5,614,216	5,744,158	
10/124,758	5,288,499	5,811,118	5,795,589	
09/314,338	6,352,716	4,973,465	6,083,530	
09/914,165	4,975,282	5,100,591	4,880,635	
10/088,796	4,861,580	5,716,526	5,922,350	
60/209,088	5,041,278	5,540,936	5,077,056	
60/270,308	5,234,634	5,683,715	5,578,320	
10/011,781	5,330,689	5,614,214	5,736,155	
60/343,251	5,409,704	5,662,930	5,837,279,	
60/343,211	4,981,692	5,766,624	4,885,172	
60/343,166	5,154,930	5,882,678	5,047,245	
60/346,284	5,948,441	5,580,899	5,171,578	
60/346,285	5,364,631	5,939,567	5,059,421	
60/346,287	5,026,557	6,118,011	4,923,854	
09/988,665	5,631,394	6,291,690	5,204,112	
60/209,088	5,677,337	6,153,736	5,252,263	
	5,681,589	6,015,716	5,376,452	
	5,840,328	5,932,242	5,616,334	
	6,030,639	6,017,557	4,963,297	
	5,009,819	6,120,797	5,525,232	
	5,415,867	6,294,191	5,399,331	
	5,049,392	6,087,325	5,380,531	
	5,171,737	6,143,716	5,389,378	
	5,626,873	6,339,069	5,552,155	

## Schedule B Attachment to Recordation Cover Sheet form PTO-1595

- 1. U.S. Patent No. 4,564,599, issued January 14, 1986 (Serial No. 06/476,495, filed March 24, 1983)
  For: Liposome Composition for Lupus Assay
- 2. U.S. Patent No.4,668,638, issued May 26, 1987 (Serial No. 06/535,884)
  For: Liposome Composition for Lupus Assay
- 3. U.S. Patent No. 4,897,384, issued January 30, 1990 (Serial No. 06/844,248)
  For: Drug Preparations of Reduced Toxicity
- 4. U.S. Patent No. 5,059,591, issued October 22, 1991 (Serial No. 07/405,623) (Re-examined, Serial No. 90/005,227) For: Drug preparations of Reduced Toxicity
- 5. U.S. Patent No.5,366,958, issued November 22, 1994 (Serial No.08/119,193)
  For: Localized Delivery Using Fibronectin
- 6. U.S. Patent No.5,000,958, issued March 19, 1991 (Serial No.06/633,481)
  For: Enhancement of Pharmaceutical Activity
- 7. U.S. Patent No.5,030,453, issued July 9, 1991 (Serial No. 06/660,573)
  For: Stable Plurilamellar Vesicles
- 8. U.S. Patent No.5,169,637, issued December 8, 1992 (Serial No.06/679, 569)
  For: Stable Plurilamellar Vesicles
- 9. U.S. Patent No.4,714,571, issued December 22, 1987 (Serial No.06/698,668)
  For: Process for Purification of Phospholipids
- 10. U.S. Patent No.4,814,111, issued March 21, 1989 (Serial No.06/928,508)

  For: Process for Purification of Phospholipids

11. U.S. Patent No.5,084,215, issued January 28, 1992 (Serial No.07/260,156)

For: Process for Purification of Phospholipids

12. U.S. Patent No.4,708,861, issued November 24,1987 (Serial No.06/695,887)
For: Liposome-Gel Compositions

13. U.S. Patent No.4,721,612, issued January 26,1988 (Serial No.06/721,630)
For: Steroidal Liposomes

14. U.S. Patent No.4,891,208, issued January 2, 1990 (Serial No.06/773,429)
For: Steroidal Liposomes

15. U.S. Patent No.5,231,112, issued July 27,1993 (Serial No.07/425,727)
For: Steroidal Liposomes

U.S. Patent No.5,288,499, issued February 22, 1994(Serial No.07/758,587)For: Steroidal Liposomes

17. U.S. Patent No.6,352,716, issued March 5, 2002 (Serial No.08/108,822)
For: Steroidal Liposomes

U.S. Patent No.4,975,282, issued December 4, 1990
 (Serial No.97/122,613)
 For: Multilamellar Liposomes Having Improved Trapping Efficiencies

20. U.S. Patent No. 4,861,580., issued August 29, 1989 (Serial No.06/911,138)
For: Alpha-Tocopherol Based Vesicles

21. U.S. Patent No.5,041,278, issued August 29, 1991 (Serial No.07/280,551)
For: Alpha-Tocopherol Based Vesicles

U.S. Patent No. 5,234,634., issued August 10, 1993(Serial No.07/599,290)For: Alpha-Tocopherol Based Vesicles

23. U.S. Patent No.5,330,689, issued July 19, 1994 (Serial No.08/039,941)
For: Alpha-Tocopherol Based Vesicles

24. U.S. Patent No.5,409,704, issued April 25, 1995 (Serial No.08/059,192)

For: Liposomes Comprising Aminoglycoside Phosphates and Methods of Production and Use

25. U.S. Patent No.4, 981,692, issued January 1, 1991 (Serial No. 07/086,467)

For: Therapeutic Treatment by Intramammary Infusion

26. U.S. Patent No.5,154,930, issued October 13, 1992 (Serial No.07/160,141)

For: Pharmacological Agent-Lipid Solution Preparation

U.S. Patent No.5,948,441, issued September 7,1999(Serial No.98/367,923)For: Method for Size Separation of Particles

28. U.S. Patent No.5,364,631, issued November 15, 1994 (Serial No.08/018,913)
For: Tocopherol-Based Pharmaceutical Systems

29. U.S. Patent No.5,026,557, issued June 25, 1991 (Serial No.07/483,263)
For: Adjuvant Composition

30. U.S. Patent No.5,631,394, issued May 20,1997 (Serial No.08/383,291)

For: Pharmaceutically Active Compounds and Liposomes and Methods of Use Thereof

31. U.S. Patent No.5,677,337, issued October 14, 1997 (Serial No. 98/547,688)

For: Methods of Treatment Using Pharmaceutically Active Ceramide-Related Compositions

32. U.S. Patent No. 5,681,589, issued October 28,1997 (Serial No.08/545,164)

For: Liposomal Ceramide-Related Compounds and the Therapeutic Use Thereof

- 33. U.S. Patent Application Serial No. 09/429,694, filed October 27, 1999
  For: Liposomal Ceramide-Related compounds and the Therapeutic Use Thereof
- 34. U.S. Patent No. 5,840,328, issued November 24, 1998
   (Serial No.08/371,541)
   For: Treatment using Arachidonic Acid Metabolite and Particulate Formulations
- U.S. Patent No.6,030,639, issued February 29, 2000
   (Serial No.08/652,259)
   For: Treatment Using Arachidonic Acid Metabolite and Particulate Formulations
- 36. U.S. Patent No.5,009,819, issued April 23, 1991 (Serial No.07/119,667)
  For: Taste Moderating Composition
- 37. U.S. Patent No.5,415,867, issued May 16,1995 (Serial No.08/105,764)
  For: High Ratio Active Agent: Lipid Complex
- 38. U.S. Patent No.5,049,392, issued September 17, 1991 (Serial No.07/298,470)
  For: Osmotically Dependent Vesicles
- 39. U.S. Patent No. 5,171,737, issued December 15, 1992 (Serial No.07/318,774)For: Emulsions
- 40. U.S. Patent No. 5,626,873, issued May 5, 1997 (Serial No.08/442,080)
  For: Emulsions
- 41. U.S. Patent No.5,100,662, issued March 31, 1992 (Serial No.07/422,047)
  For: Steroidal Liposomes Exhibiting Enhanced Stability
- 42. U.S. Patent No.5,376,381, issued December 27, 1994 (Serial No.97/649,237)
  For: Integrity Protected Gelatin
- U.S. Patent No.5,200,393, issued April 6, 1993
   (Serial No.07/758,276)
   For: Lipid Excipient for Nasal Delivery and Topical Application

44. U.S. Patent No.5,762,958, issued June 9,1998 (Serial No.98/602,669) Multilipid Component Ether Liposomes For:

U.S. Patent No. 5,965,159, issued October 12, 1999 45. (Serial No. 09/017,440)

For: Etherlipid-Containing Multiple Lipid Liposomes

U.S. Patent No.5,942,246, issued August 24,1999 46. (Serial No.09/017,366)

Etherlipid-Containing Multiple Lipid Liposomes For:

47. U.S. Patent No.6,007,839, issued December 28, 1999 (Serial No.09/017,439)

For: Preparation for Etherlipid-Containing Multiple Lipid Liposomes

48. U.S. Patent No.6,180,137, issued January 30, 2001 (Serial No.09/390,395)

Etherlipid-Containing Multiple Lipid Liposomes For:

- U.S. Patent Application Serial No. 09/540,050, filed March 3, 2000 49. D and L Etherlipid Stereoisomers and Liposomes For:
- U.S. Patent Application Serial No.09/976,936, filed October 11, 2001 50. Etherlipid-Containing Multiple Lipid Liposomes For:
- U.S. Patent No.5,897,873, issued April 27, 1999 51. (Serial No.98/392,676) Affinity Associated Vaccine For:
- 52. U.S. Patent No.5,820,848, issued October 13, 1998 (Serial No.08/315,988)

Methods of Preparing Interdigitation-Fusioni Liposomes and Gels Which For: Encapsulate a Bioactive Agent

U.S. Patent No.6,086,851, issued July 11,2000 53. (Serial No.08/881,651)

> Pharmaceutical Compositions Containing interdigitation-Fusion Liposomes and For: Gels

U.S. Patent Application Serial No. 09/645,973, filed April 27, 2000 54. Interdigitation-Fusion Gels For:

U.S. Patent No.6,090,406, issued July 18, 2000(Serial No. 07/485,388)For: Potentiation Of Immune Responses With Liposomal Adjuvants

56. U.S. Patent No.5,916,588, issued June 29,1999 (Serial No. 08/452,549)

For: Immunizing Dosage Forms

57. U.S. Patent No.5,614,216, issued March 25, 1997 (Serial No. 08/442,079)

For: Synthetic Lung Surfactant

58. U.S. Patent No.5,811,118, issued September 2, 1998 (Serial No. 08/333,975)

For: Methods of Treatment Using Unilamellar Liposomal Arachidonic Acid Metabolite Formulations

59. U.S. Patent No.4,973,465, issued November 27, 1990 (Serial No. 07/364,481)

For: Microcrystals Comprising an Active Substance Having an Affinity for Phospholipids and at Least One Phospholipid, Process for Preparation

60. U.S. Patent No.5,100,591, issued March 31, 1992 (Serial No. 07/528,053)

For: Method of Separating Materials From Liposomes or Lipid Co.

For: Method of Separating Materials From Liposomes or Lipid Complexes

61. U.S. Patent No. 5,716,526, issued February 10, 1998 (Serial No. 08/599,869)

For: Method of Separating Materials from Liposomes or Lipid Complexes

62. U.S. Patent No.5,540,936, issued July 30, 1996 (Serial No. 08/253,145)

For: Methods of Producing Liposomes

63. U.S. Patent Application Serial No. 08/442,077, filed May 16,1995 For: Method for Controlling the Size of Liposomes

64. U.S. Patent No. 5,683,715, issued November, 1997 (Serial No. 08/482,359)

For: Taxane-Containing Phosphatidylcholine Liposomes

65. U.S. Patent Application Serial No. 09/398,934, filed September 1, 1999 For: Reduction of Liposome-Induced Adverse Physiological Reactions

U.S. Patent No.5,614,214, issued March 25, 1997
 (Serial No. 08/247,053)
 For: Reduction of Liposome-Induced Adverse Physiological Reactions

67. U.S. Patent No. 5,662,930, issued September 2, 1997 (Serial No. 08/433,665)

For: Reduction of Liposome-Induced Adverse Physiological Reactions

68. U.S. Patent No.5,766,624, issued June 16, 1998 (Serial No.08/449, 598)
For Liposomal Defensins

69. U.S. Patent No.5,882,678, issued March 16, 1999
(Serial No.08/339,964)
For Interdigitation-Fusion Liposomes Containing Arachidonic Acid Metabolites

70. U.S. Patent No.5,580,899, issued December 3, 1996 (Serial No.08/474,888)

For Hydrophobic Taxane Derivatives

71. U.S. Patent No.5,939,567, issued August 17, 1999
(Serial No.08/988,120)
For Methods of Combinatorial Therapy Using Hydrophobic Taxane Derivatives

72. U.S. Patent No.6,118,011, issued September 12, 2000 (Serial No.08/753,650)

For Preparation of Liposomal Taxanes

73. U.S. Patent No. 6,291,690, issued September 18, 2001 (Serial No.09/567,366)

For Hydrophobic Taxane Derivatives

74. U.S. Patent No.6,153,736, issued November 28, 2000 (Serial No.98/722,881)
For Modified Ether Glyceroglycolipids

75. U.S. Patent Application Serial No. 09/644,470, filed August 23, 2000 For Modified Ether Glyceroglycolipids

76. U.S. Patent No.6,015,716, issued January 18, 2000 (Serial No.08/679,046)

For Detection of Endotoxin Levels in Liposomes, Lipid Bilayers and Lipid Complexes

77. U.S. Patent No.5,932,242, issued August 3,1999
(Serial No.08/720,997)
For Ether Lipid-containing Pharmaceutical Compositions and Therapeutic Uses
Thereof

78. U.S. Patent No. 6,017,557, issued January 25, 2000 (Serial No.08/950,773)

For Ether Lipid-containing Pharmaceutical Compositions and Therapeutic Uses
Thereof

79. U.S. Patent No.6,120,797, issued September 19,2000
(Serial No.08/951,956)
For N-Acyl Phosphatidylethanolamine Mediated Liposome Drug Delivery

80. U.S. Patent No. 6,294,191, issued September 25, 2001
(Serial No.09/487,953)
For N-Acyl Phosphatidylethanolamine Mediated Liposomal Drug Delivery

81. U.S. Patent No.6,087,325, issued July 11, 2000 (Serial No.08/950,618)
For Peptide-Lipid Conjugates

82. U.S. Patent No.6,143,716, issued November 7, 2000 (Serial No.09/168,010)

For Liposomal Peptide-Lipid Conjugates, and Delivery Using Same

83. U.S. Patent No.6,339,069, issued January 15,2002
(Serial No.09/343,650)
For Peptide-Lipid Conjugated, Liposomes and Liposomal Drug Delivery

84. U.S. Patent No. 5,756,774, issued May 26, 1998 (Serial No.08/794,957)
For Novel Synthesis of Myo-Inositol Phosphates

85. U.S. Patent No.4,666,831, issued May 19,1987 (Serial No.06/702,555)
For Improved Lipid-Dependent Diagnostic Assays

86. U.S. Patent No.4,698,299, issued October 6, 1987 (Serial No.06/831,255)
For Lipid-Dependent Diagnostic Assays

87. U.S. Patent No. 6,261,792, issued July 17, 2001 (Serial No.08/44,567)
For Lipid-Dependent Diagnostic Assays

88. U.S. Patent No.4,522,803, issued June 11, 1985 (Serial No.06/476/496)
For Stable Plurilamellar Vesicles

89. U.S. Patent No.4,588,578, issued May 13, 1986 (Serial No. 06/521,176)
For Lipid Vesicles Prepared in a Monophase

90. U.S. Patent No.5,429,823, issued July 4, 1995
(Serial No.08/303,592)
For Phospholipid Composition and Liposomes Made Therefrom

91. U.S. Patent No.5,783,210, issued June 21, 1998 (Serial No.08/453,132)
For Phospholipid Composition

92. U.S. Patent No.5,556,580, issued September 17, 1996
(Serial No.08/437, 906)
For Liposome Continuous Size Reduction Method and Apparatus

93. U.S. Patent No. 5,583,052, issued December 10,1996 (Serial No.08/447,660)

For Formulation Preparation Device

94. U.S. Patent No. 5,622,713, issued April 22, 1997 (Serial No. 08/375,190)

For Method for Detoxifying Animal Suffering from Overdose

95. U.S. Patent No.5,008,050, issued April 16, 1991
(Serial No.07/310,495)
For Extrusion Technique for Production Unilamellar Vesicles

96. U.S. Patent No.5,616,341, issued April 1, 1997
(Serial No.08/112,875)
For Low Toxicity Formulations of Liposomal Antineoplastic Agents

97. U.S. Patent No.5,744,158, issued April 28,1998
(Serial No.08/450,830)
For Methods of Treatment Using High Drug:Lipid Formulations of Liposomal Antineoplastic Agents

98. U.S. Patent No.5,795,589, issued August 18, 1998 (Serial No.08/794,988)
For Liposomal-Antineoplastic Agent Compositions

99. U.S. Patent No. 6,083,530, issued July 4, 2000
(Serial No.09/084,526)
For High Drug: Lipid Formulations of Liposomal Antineoplastic Agents

100. U.S. Patent No.4,880,635, issued November 14,1989 (Serial No. 06/759,419) (Re-examination Serial No. 09/003,125, issued July 2, 1996) For Dehydrated Liposomes

101. U.S. Patent No.5,922,350, issued July 13,1999 (Serial No. 08/876,938)
For Dehydrated Liposomes

102. U.S. Patent Application Serial No.09/715,798, filed November 17, 2000 For Encapsulation of Ionizable Agents in Liposomes

103. U.S. Patent No.5,077,056, issued December 31, 1991 (Serial No.07/284,751)

For Encapsulation of Antineoplastic Agents in Liposomes

104. U.S. Patent No.5,578,320, issued November 26,1996 (Serial No.08/022,819)
For Dehydrated Liposomes

105. U.S. Patent No. 5,736,155, issued April 7,1998
(Serial No.08/461,212)
For Encapsulation of Antineoplastic Agents in Liposomes

106. U.S. Patent No.5,837,279, issued November 17,1998 (Serial No.08/450,831)

For Encapsulation of Ionizable Agents in Liposomes

U.S. Patent No. 4,885,172, issued December 5, 1989
 (Serial No.06/941,913)
 For Novel Compositions for Targeting, Storing, and Loading of Liposomes

U.S. Patent No.5,047,245, issued September 10,1991
 (Serial No.07/399,642)
 For Novel Compositions for Targeting, Storing, and Loading of Liposomes

U.S. Patent No.5,171,578, issued December 15,1992
 (Serial No.07/711,294)
 For Novel Compositions for Targeting, Storing and Loading of Liposomes

U.S. Patent No.5,059,421, issued October 22, 1991
 (Serial No.07/370,650)
 For Preparation of Targeted Liposome Systems of a Defined Size Distribution

U.S. Patent No.4,923,854, issued May 8, 1990(Serial No.06/821,366)For Solubilization of Hydrophobic Materials Using Lysophospholipid

U.S. Patent Application Serial No.07/323,182, filed March 13, 1989
 For Methods and Compositions Using Liposome-Encapsulated Non-Steroidal Anti-Inflammatory Drugs

113. U.S. Patent No.5,204,112, issued April 20,1993 (Serial No.07/061,837)

For Induction of Asymmetry in Vesicles

114. U.S. Patent No.5,252,263, issued October 12, 1993 (Serial No.07/854,107)

For Induction of Asymmetry in Vesicles

115. U.S. Patent No.5,376,452, issued December 27, 1994 (Serial No.08/132,711)

For Induction of Asymmetry in Vesicles

U.S. Patent Application Serial No. 08/439,227, filed May 11, 1995
 For Nonsteroidal Anti-inflammatory Compositions and Method of Preparation and Use

117. U.S. Patent Application Serial No.08/430,661, filed April 28, 1995 For Low Toxicity Drug-Lipid System

118. U.S. Patent No.5,616,334, issued April 1, 1997 (Serial No.08/430,699)
For Low Toxicity Drug-Lipid System

119. U.S. Patent Application Serial No.10/132,151, filed April 26, 2002 For Low Toxicity Drug-Lipid System

120. U.S. Patent No. 4,963,297, issued October 16,1990 (Serial No.07/136,267)

For Spontaneous Vesiculation of Multilamellar Liposomes

121. U.S. Patent No.5,525,232, issued June 11, 1996
 (Serial No. 08/137,371)
 For Method of Entrapment of Cationic Species in Lamellar Vesicles

- 122. U.S. Patent No.5,399,331, issued March 21, 1995 (Serial No.07/946,806)

  For Method for Protein-Liposome Coupling
- U.S. Patent No.5,380,531, issued January 10, 1995(Serial No.07/896,509)For Accumulation of Amino Acids and Peptides into Liposomes
- U.S. Patent No.5,389,378, issued February 14, 1995
   (Serial No.07/990,023)
   For Benzoporphyrin Vesicles and Their use in Photodynamic Therapy
- U.S. Patent No.5,552,155, issued September 3, 1996
  (Serial No. 08/226,642)
  For Fusogenic Liposomes and Method for Making and Using Same
- U.S. Patent Application Serial No.08/472,843, filed June 7, 1995
   For Method for Loading Lipid Like Vesicles with Drugs or Other Chemicals
- 127. U.S. Patent No.5,703,117, issued December 30, 1997 (Serial No.08/712,684)
  For Hydrolysis-Promoting Hydrophobic Taxane Derivatives
- 128. U.S. Patent No.6,051,600, issued April 18, 2000 (Serial No.08/805,184)

  For Hydrolysis-Promoting Hydrophobic Taxane Derivatives
- 129. U.S. Patent No.6,107,332, issued August 22, 2000 (Serial No.09/249,004)

  For Hydrolysis-Promoting Hydrophobic Taxane Derivatives
- 130. U.S. Patent No.6,392,063, issued May 21, 2002 (Serial No.09/618,872) For Hydrolysis-Promoting Hydrophobic Taxane Derivatives
- 131. U.S. Patent Application Serial No.09/940,672, filed August 29, 2001 For Hydrolysis-Promoting Hydrophobic Taxane Derivatives
- 132. U.S. Patent Application Serial No.10/124,758, filed April 16, 2002 For Hydrolysis-Promoting Hydrophobic Taxane Derivatives
- 133. U.S. Patent No. 5,082,664, issued January 21, 1992 (Serial No.07/195,228)
  For Prostaglandin-Lipid Formulations

- 134. U.S. Patent No. 5,262,168, issued November 16, 1993 (Serial No.07/821,648)
  For Prostaglandin-Lipid Formulations
- 135. U.S. Patent No.5,925,375, issued July 20, 1999
  (Serial No.08/333,770)
  For Multilamellar Liposomal Arachidonic Acid Metabolite Formulations
- 136. U.S. Patent No.5,188,951, issued February 23,1993
  (Serial No.07/694,669)
  For Enzymatic Synthesis of Soluble Phosphatides from Phospholipids
- 137. U.S. Patent Application Serial No.09/314,338, filed May 19,1999 For Novel Particulate Formulations
- 138. U.S. Patent Application Serial No.09/914,165, filed December 26, 2001 For Encapsulation of Bioactive Complexes in Liposomes
- 139. U.S. Patent Application Serial No. 10/088,796, filed March 22, 2002 For Solid Phase Assay
- 140. U.S. Patent Application Serial No.60/209,088, filed June 2, 2000 For Modular Targeted Liposomal Delivery System
- 141. U.S. Patent Application Serial No. 60/270,308, filed February 21, 2001 For Enantiomers of Unsaturated Alkyllysophosphonocholines and Use as Anti-neoplastics
- 142. U.S. Patent Application Serial No. 10/011,781, filed December 11, 2001 For C-Glucosal Ether Lipids
- 143. U.S. Patent Application Serial No.60/343,251, filed December 31, 2001 For Efficient Nucleic Acid Encapsulation Into Medium Sized Liposomes
- 144. U.S. Patent Application Serial No.60/343,211, filed December 31, 2002 For Efficient Liposomal Encapsulation under Mild Conditions
- 145. U.S. Patent Application Serial No.60/343,166, filed December 31, 2001 For Efficient Liposomal Encapsulation
- U.S. Patent Application Serial No.60/346,284, filed January 9, 2002
   For Efficient Nucleic Acid Encapsulation into Medium Sized Liposomes
- 147. U.S. Patent Application Serial No. 60/346,285, filed January 9, 2002 For Efficient Liposomal Encapsulation Under Mild Conditions

- 148. U.S. Patent Application Serial No.60/346,287, filed January 9, 2002 For Efficient Liposomal Encapsulation
- 149. U.S. Patent Application Serial No.09/988,665, filed November 20, 2001 For Liposome Extrusion Process
- U.S. Patent No. 5,762,957, issued June 9, 1998(Serial No. 08/474,382)For Method for Loading Lipid Like Vesicles with Drugs or Other Chemicals
- 151. U.S. Patent Application Serial No. 60/209,088

  For Modular Targeted Liposomal Delivery System

PAGE 1

## The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"THE LIPOSOME COMPANY, INC.", A DELAWARE CORPORATION,
WITH AND INTO "ELAN PHARMACEUTICALS, INC." UNDER THE NAME OF

WITH AND INTO "ELAN PHARMACEUTICALS, INC." UNDER THE NAME OF "ELAN PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWENTY-EIGHTH DAY OF DECEMBER, A.D. 2001, AT 10:02 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE THIRTY-FIRST DAY OF DECEMBER, A.D. 2001, AT 12 O'CLOCK A.M.

Darriet Smith Windson Sacrosom of State

AUTHENTICATION: 1767283

DATE: 05-08-02 PATENT

REEL: 012958 FRAME: 0617

2104559 8100M

020295553

STATE OF DELAWARE SECRETARY OF STATE DIVISION OF CORPORATIONS FILED 10:02 AM 12/28/2001 010674852 - 2104559

CERTIFICATE OF MERGER OF

THE LIPOSOME COMPANY, INC.

WITH AND INTO

ELAN PHARMACEUTICALS, INC. (Pursuant to Section 251 of the General Corporation Law of Delaware)

\*\*\*\*\*

The undersigned corporation organized and existing under and by virtue of the General Corporation Law of Delaware,

DOES HEREBY CERTIFY:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

NAME

STATE OF INCORPORATION

The Liposome Company, Inc.

Delaware

Elan Pharmaceuticals, Inc.

Delaware

<u>SECOND</u>: That an Agreement and Plan of Merger, dated as of December 28, 2001 (the "Merger Agreement"), by and among The Liposome Company, Inc. and Elan Pharmaceuticals, Inc. has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Section 251 of the General Corporation Law of Delaware.

THIRD: That Elan Pharmaceuticals, Inc. shall be the surviving corporation (the "Surviving Corporation").

FOURTH: That the Amended and Restated Certificate of Incorporation of Elan Pharmaceuticals, Inc., which will survive the merger, shall be the Certificate of Incorporation of the Surviving Corporation.

Liposome Cartificate of Herger

-2-

FIFTH: That the executed Merger Agreement is on file at an office of the Surviving Corporation, the address of which is 800 Gateway Boulevard, South San Francisco, California 94080.

<u>SIXTH</u>: That a copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of any constituent corporation.

<u>SEVENTH</u>: That this Certificate of Merger shall be effective at midnight on December 31, 2001.

Dated: December 28, 2001

ELAN PHARMACEUTICALS, INC.

By

Name:

Lisabeth F. Murphy

Title: Vice President &

Secretory

ATTEST:

**RECORDED: 06/14/2002** 

Lipopone Cartificate of Mesper